选择性孕激素受体调节剂醋酸乌利司他对人类子宫内膜的影响
该观察性研究分析了9例接受醋酸乌利司他(口服5 mg/日,9–12周)治疗的子宫肌瘤患者子宫内膜,并与增殖期和分泌期对照各9例比较。UPA引起与PAEC一致的形态学改变,改变雌孕雄激素受体及孕激素调节基因表达,腺体和间质细胞增殖(Ki67)低于增殖期。
要点
- UPA治疗9–12周引起子宫内膜形态学改变,符合孕激素受体调节剂相关子宫内膜改变(PAEC)。
- UPA治疗后PR和AR表达模式较增殖期或分泌期样本发生显著改变。
- UPA治疗样本中Ki67阳性细胞核(细胞增殖)低于增殖期样本。
核心结论
- 醋酸乌利司他给药改变性激素受体和孕激素调节基因的表达,并与腺体和间质细胞增殖水平低相关。
研究设计与样本
- 观察性研究,进行组织学和分子分析以描述UPA治疗对子宫内膜的影响。
- 子宫内膜样本(n=9)来自39至49岁、因子宫肌瘤接受UPA(口服5 mg每日)治疗9–12周后行子宫切除术的女性。
- 对照增殖期(n=9)和分泌期(n=9)子宫内膜来自38–52岁子宫肌瘤女性的机构组织档案。
- 研究场所为大学研究所,子宫内膜活检经机构伦理批准和书面知情同意后采集。
主要发现
- UPA诱导子宫内膜组织形态学改变,与PAEC一致。
- 与增殖期或分泌期样本相比,检测到PR和AR表达模式的显著改变。
- 与分泌期样本相比,IGFBP-1、FOXO1、IL-15、HAND2、IHH和HOXA10编码的mRNA表达模式有显著变化,与子宫内膜中低激动剂活性一致。
- UPA治疗样本中FOXM1(与细胞周期进程相关的转录因子)编码的mRNA表达低。
- UPA治疗女性样本中细胞增殖(Ki67阳性细胞核)低于增殖期样本。
局限性
- 研究仅深入分析了少量特征明确的患者。
- SPRM(UPA)给药对症状控制的影响在形态学、分子和细胞层面尚待确定。
- 原文结论指出这些数据支持SPRM类化合物作为重型月经出血有效长期药物治疗的后续开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the impact of administration of the selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA) on the endometrium of women with fibroids? SUMMARY ANSWER: UPA administration altered expression of sex-steroid receptors and progesterone-regulated genes and was associated with low levels of glandular and stromal cell proliferation. WHAT IS KNOWN ALREADY: Administration of all SPRM class members results in PAEC (progesterone receptor modulator associated endometrial changes). Data on the impact of the SPRM UPA administration on endometrial sex-steroid receptor expression, progesterone (P)-regulated genes and cell proliferation are currently lacking. STUDY DESIGN SIZE, DURATION: Observational study with histological and molecular analyses to delineate impact of treatment with UPA on endometrium. Endometrial samples (n = 9) were collected at hysterectomy from women aged 39 to 49 with uterine fibroids treated with UPA (oral 5 mg daily) for 9-12 weeks. Control proliferative (n = 9) and secretory (n = 9) endometrium from women aged 38-52 with fibroids were derived from institutional tissue archives. PARTICIPANTS/MATERIALS, SETTING, METHODS: Study setting was a University Research Institute. Endometrial biopsies were collected with institutional ethical approval and written informed consent. Concentrations of mRNAs encoded by steroid receptors, P-regulated genes and factors in decidualised endometrium were quantified with qRT-PCR. Immunohistochemistry was employed for localization of progesterone (PR, PRB), androgen (AR), estrogen (ERα) receptors and expression of FOXO1, HAND2, HOXA10, PTEN homologue. Endometrial glandular and stromal cell proliferation was objectively quantified using Ki67. MAIN RESULTS AND THE ROLE OF CHANCE: UPA induced morphological changes in endometrial tissue consistent with PAEC. A striking change in expression patterns of PR and AR was detected compared with either proliferative or secretory phase samples. There were significant changes in pattern of expression of mRNAs encoded by IGFBP-1, FOXO1, IL-15, HAND2, IHH and HOXA10 compared with secretory phase samples consistent with low agonist activity in endometrium. Expression of mRNA encoded by FOXM1, a transcription factor implicated in cell cycle progression, was low in UPA-treated samples. Cell proliferation (Ki67 positive nuclei) was lower in samples from women treated with UPA compared with those in the proliferative phase. LARGE SCALE DATA: N/A. LIMITATIONS REASONS FOR CAUTION: A small number of well-characterized patients were studied in-depth. The impacts on morphology, molecular and cellular changes with SPRM, UPA administration on symptom control remains to be determined. WIDER IMPLICATIONS OF THE FINDINGS: P plays a pivotal role in endometrial function. P-action is mediated through interaction with the PR. These data provide support for onward development of the SPRM class of compounds as effective long-term medical therapy for heavy menstrual bleeding. STUDY FUNDING/COMPETING INTEREST(S): H.O.D.C. received has clinical research support for laboratory consumables and staff from Bayer Pharma Ag and provides consultancy advice (no personal remuneration) for Bayer Pharma Ag, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc.; A.R.W.W. has received consultancy payments from Bayer, Gedeon Richter, Preglem SA, HRA Pharma; L.H.R.W., A.A.M., R.M., G.S. and P.T.K.S. have no conflicts of interest. Study funded in part from each of: Medical Research Council (G1002033; G1100356/1; MR/N022556/1); National Health Institute for Health Research (12/206/520) and TENOVUS Scotland.
引用
- Whitaker LH, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod. 2017. PMID: 28130434. doi:10.1093/humrep/dew359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。